# DESCRIPTION

## BACKGROUND OF THE INVENTION

- motivate genetic mechanisms

## SUMMARY OF THE INVENTION

- define bifunctional compound
- describe dTAG system

## DETAILED DESCRIPTION OF THE INVENTION

- define technical terms
- specify meaning of singular forms
- define "about" and transitional phrases
- define alkyl, alkenyl, alkoxyl, and alkoxylene
- define cyclic groups, including carbocyclic and heterocyclyl
- provide examples of heterocyclyls and their variations
- define aryl and heteroaryl groups
- describe substituents and their permissible valence
- define binding interactions between targeting ligand and protein
- introduce bifunctional compound structure and formula I
- describe pharmaceutically acceptable salts and stereoisomers
- discuss isotopic derivatives, chiral centers, and solvated forms

### Targeting Ligands

- define targeting ligand structure

### Linkers

- describe linker structure
- provide examples of linkers

### Degrons

- describe degron structure

### Methods of Synthesis

- outline method for making bifunctional compounds

### Proteins of Interest

- list proteins that can be targeted by dTAG system

### Methods of Use

- describe in vitro methods
- describe in vivo methods
- outline genetic modification of cells
- detail insertion of dTAG sequence
- explain CRISPR-Cas9 system
- describe donor sequence introduction
- outline CRISPR complex formation
- discuss Cas proteins and guide sequences
- introduce CRISPR-Cas system for genome editing
- describe methods of delivering nucleic acid sequences to cells
- outline viral vector approaches for gene transfer
- discuss non-viral vector delivery systems
- describe methods of introducing CRISPR-Cas polynucleotides into cells
- outline methods of delivering nucleic acids encoding dTAG in frame in genomic locus
- discuss non-CRISPR-CAS viral and non-viral based gene transfer methods
- describe additional methods of delivery, including EnGenelC delivery vehicles

### Chimeric Antigen Receptor Protein (CAR)-dTAG Fusion Proteins

- introduce CAR-T cell therapy
- describe limitations of CAR-T cell therapy
- motivate need for safety strategies
- describe CAR-dTAG fusion protein
- detail structure of CAR-dTAG fusion protein
- describe preparation of nucleic acid encoding CAR
- outline use of CAR-expressing cells as therapeutic agents

### Dosage Amounts

- define therapeutically effective amount

### Pharmaceutical Kits

- describe pharmaceutical kits for CAR-dTAG fusion proteins

## EXAMPLES

- describe synthesis of compounds

### Example 1: Synthesis of (R)-3-(3,4-dimethoxyphenyl)-1-(2-(2-((7-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-7-oxoheptyl)amino)-2-oxoethoxy)phenyl)propyl (S)-1-((S)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate (1)

- prepare compound A
- synthesize compound 1 from compound A

### Example 2: Synthesis of (R)-3-(3,4-dimethoxyphenyl)-1-(2-(2-((7-(((S)-1-((2R,4S)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-7-oxoheptyl)amino)-2-oxoethoxy)phenyl)propyl (S)-1-((S)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate (2)

- synthesize compound 2 from intermediate E

### Example 3: Synthesis of (R)-3-(3,4-dimethoxyphenyl)-1-(2-(((S)-16-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carbonyl)-17,17-dimethyl-2,14-dioxo-6,9,12-trioxa-3,15-diazaoctadecyl)oxy)phenyl)propyl (S)-1-((S)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate (3)

- synthesize compound 3 from intermediate A

### Example 4: Synthesis of (R)-3-(3,4-dimethoxyphenyl)-1-(2-(O)-16-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-17,17-dimethyl-2,14-dioxo-6,9,12-trioxa-3,15-diazaoctadecyl)oxy)phenyl)propyl (9-14(9-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate (4)

- synthesize compound 4 from VHL ligand 1

### Example 5: Anti-Proliferation in NIH/3T3 Cells Expressing FKBP12F36V-KRASG12V by ATPlite™ Assay

- measure anti-proliferative effects of dTAG molecules

### Example 6: Immunoblotting of PATU-8902 LACZ-FKBP12F36V Clone

- monitor LACZ-FKBP12F36V degradation

### Example 7: Immunoblotting of PATU-8902 LACZ-FKBP12F36V Clone

- monitor LACZ-FKBP12F36V and CDK9 degradation

### Example 8: Immunoblotting of PATU-8902 FKBP12F36V-KRASG12V; KRAS−/− Clone

- perform immunoblotting to determine protein levels

### Example 9: Immunoblotting of PATU-8902 FKBP12F36V-KRASG12V KRAS−/− Clone

- perform immunoblotting to determine protein levels
- test effect of compound 1 on protein degradation
- test effect of proteasome-inhibitor and Nedd8 activating enzyme inhibitor on protein degradation

